Cardioprotection by anti-ischaemic and cytoprotective drugs

Area of Science:

• Cardiology
• Pharmacology

Background:

• Impaired cardiac energetics can lead to sudden coronary death (SCD) and myocardial necrosis.
• Cardioprotection involves anti-ischemic (vascular supply vs. demand) and cytoprotective (cellular integrity) mechanisms.
• Full cardioprotection requires prevention of SCD and limitation of infarct size.

Purpose of the Study:

• To evaluate the efficacy of different cardioprotective agents in preventing SCD and limiting infarct size.
• To determine if anti-ischemic or cytoprotective effects alone or in combination are sufficient for full cardioprotection.

Main Methods:

• Review of existing studies on cardioprotective agents including beta-blockers, linoleic acid-rich diets, lidocaine, 7-oxoPGI2, and nonsteroidal anti-inflammatory drugs (NSAIDs).
• Analysis of agent effects on myocardial oxygen demand, prevention of early post-occlusion ventricular fibrillation (EPVF), SCD, and infarct size limitation.

Main Results:

• Pindolol (beta-blocker) reduced O2 demand and protected against SCD/EPVF but did not limit infarct size.
• Linoleic acid-rich diet and lidocaine showed cytoprotective action against SCD/EPVF but failed to limit infarct size.
• 7-oxoPGI2, possessing both anti-ischemic and cytoprotective effects, did not protect against SCD/EPVF or limit infarct size.
• NSAIDs (salicylates, sulfinpyrazon) reduced O2 demand and protected against SCD/EPVF, while also effectively limiting infarct size.

Conclusions:

• Neither anti-ischemic nor cytoprotective effects alone are sufficient for complete cardioprotection.
• NSAIDs demonstrate a dual benefit, offering both anti-ischemic and cytoprotective actions that effectively limit infarct size and prevent SCD.
• Further research into NSAIDs may yield novel therapeutic strategies for managing myocardial infarction.